Roivant's experimental lupus therapy misses key goal in mid-stage trial
Roivant Sciences announced that its FcRn inhibitor, IMVT-1402 (imeroprubart), failed to meet the primary endpoint in a Phase 2b study for a form of lupus. The treatment did not improve symptoms compared to placebo, according to the company's Wednesday disclosure. This setback affects one of Roivant's leading autoimmune pipeline assets.
This mid-stage failure underscores the inherent uncertainty in autoimmune drug development, where patient heterogeneity and complex disease mechanisms often confound promising preclinical data. IMVT-1402 belongs to a class of FcRn inhibitors designed to reduce pathogenic antibodies, a strategy that has shown success in other antibody-mediated conditions. However, lupus presents a particularly challenging therapeutic landscape, with many targeted agents failing to outperform placebo in trials despite strong biological rationale. Roivant’s setback highlights the need for more precise patient selection and biomarkers to predict response, as the company now faces reassessing the program’s future alongside its broader immunology portfolio.
If this therapy ultimately does not advance, lupus patients may see fewer near-term options, though other FcRn inhibitors remain in development. The failure could temper investor enthusiasm for similar approaches, potentially slowing funding for related research. However, it may also sharpen focus on more tailored trial designs, benefiting future patients by improving how experimental drugs are evaluated.